Long-term survival after salvage pemetrexed for refractory primary T-cell lymphoma of the CNS.

Publication Title

CNS Oncol

Authors

Andy Liu, Pacific Neuroscience Institute & Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA 90404, USA.
Huda Alalami
Xuemo Fan
Chirag Patil
Jaya M Gill, Pacific Neuroscience Institute & Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA 90404, USA.Follow
Santosh Kesari, Pacific Neuroscience Institute & Saint John's Cancer Institute at Providence Saint John's Health Center, Santa Monica, CA 90404, USA.Follow
Jethro Hu

Document Type

Article

Publication Date

9-1-2023

Keywords

california; santa monica; sjci

Abstract

Primary T-cell CNS lymphoma is a rare and aggressive malignancy. High-dose methotrexate (MTX) based chemotherapy regimens are used as standard first-line treatment, followed by consolidative strategies to improve the duration of response. Although MTX-based therapy has been shown to be efficacious, treatment options for MTX-refractory disease are not well-defined. Here, we report a case of a 38-year-old man with refractory primary T-cell CNS lymphoma who demonstrated a complete response to pemetrexed treatment. He subsequently received conditioning chemotherapy consisting of thiotepa, busulfan and cyclophosphamide followed by autologous stem cell transplantation. The patient continues to remain recurrence-free to date at 9 years post-treatment.

Clinical Institute

Neurosciences (Brain & Spine)

Clinical Institute

Cancer

Specialty/Research Institute

Oncology

Specialty/Research Institute

Neurosciences

DOI

10.2217/cns-2022-0021